| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 70.38 | 5.8% | 9.6% |
| Total Income | 70.38 | 5.8% | 9.6% |
| Expenditure | 49.98 | 2.5% | 3.9% |
| PBT | 22.19 | 12.8% | 22.8% |
| Net Profit | 17.05 | 8.7% | 23.7% |
| OPM | 28.98% | 2.27pp | 3.85pp |
| NPM | 24.23% | 0.67pp | 2.77pp |
| EPS | 0.75 | 8.7% | 22.9% |
LeMaitre Vascular Reports Q2 2026 Results, Announces Dividend, and Provides Guidance
05 Aug 2026 · 5 Aug, 2:13 am
Summary
LeMaitre Vascular announced strong second quarter 2026 results, with sales reaching $70.4 million, up 10% year-over-year, driven by robust performance in key product categories like Artegraft. The company saw significant improvements in profitability, with gross margin rising to 72.1% and operating income increasing by 26% to $20.4 million, leading to a 23% rise in diluted EPS to $0.74. Management highlighted the successful international launch of Artegraft and provided optimistic guidance for the remainder of 2026, projecting full-year sales growth of 11% to a range of $274.3 million to $278.3 million.
Key Highlights
- 1
LeMaitre Vascular reported Q2 2026 sales of $70.4 million, representing a 10% increase compared to Q2 2025.
- 2
Gross margin for Q2 2026 was 72.1%, an increase of 210 basis points year-over-year.
- 3
Operating income grew by 26% to $20.4 million in Q2 2026.
- 4
Diluted Earnings Per Share (EPS) for Q2 2026 was $0.74, a 23% increase from the prior year.
- 5
Artegraft sales increased by 34% in the quarter, with grafts, carotid shunts, and patches all posting records.
- 6
The company provided guidance for Q3 2026, expecting sales between $66.3 million and $68.3 million, with an organic growth of 11%.
- 7
Full Year 2026 guidance projects sales between $274.3 million and $278.3 million, an 11% increase year-over-year.
Management Comments
George LeMaitre
Our focus on the Artegraft international launch paid off in Q2. The product is now approved in 56 countries, accounting for 21% of sales. So our largest product is now our fastest-growing product. To underpin the Artegraft launch and pave the way for RFA, we continue to build our sales force, go direct in new countries and we’re now undertaking six international warehouse expansions. $376m of cash provides strategic optionality.
Informational and educational content only. Not investment advice.